Background and Purpose-To investigate the effect of short-term high-dose atorvastatin on blood and plaque inflammation in patients with carotid stenosis. Methods-Twenty patients undergoing carotid endarterectomy without previous statin treatment were randomized to receive either atorvastatin 80 mg/d (nϭ11) or no statins (nϭ9) 
A therosclerosis results from passive lipid deposition in the vascular wall, inducing an active inflammatory process. Nuclear factor-B (NF-B) is activated in the vulnerable region of human atherosclerotic plaques and in peripheral blood mononuclear cells (PBMCs) of patients with carotid atherosclerosis. 1 This transcription factor regulates the expression of monocyte chemoattractant protein-1 (MCP-1) and cyclooxygenase-2 (COX-2), an inducible enzyme that enhances the production of the chemoattractant prostaglandin E 2 (PGE 2 ) .
Clinical trials with statins demonstrated a marked reduction in cardiovascular mortality, probably in part, by modulating the inflammatory component of plaques. 2 Intensive statin treatment reduces endothelial dysfunction and thrombotic events in short periods of treatment. 3, 4 We analyzed whether treatment with high doses of atorvastatin decrease inflammation in PBMCs and carotid atherosclerotic plaques in 1 month in patients with carotid stenosis Ն70% without previous statin treatment.
Methods
Patients with inflammatory or neoplastic disease, major surgery, or myocardial infarction in the previous 6 months, or those receiving antiinflammatory drugs (except acetylsalicylic acid up to 325 mg/d) or statins in the previous year were excluded. Informed consent was obtained, blood was drawn, and patients were allocated by using a random number table to receive either atorvastatin 80 mg/d (nϭ11) or no statin (nϭ9) until scheduled carotid endarterectomy was performed. At surgery, blood samples and atherosclerotic plaques were collected. The study was approved by the local ethical committee.
Blood Studies
Total cholesterol, low-density lipoproteins, triglycerides, and highdensity lipoproteins were measured by enzymatic assays (Sigma), and MCP-1 and PGE 2 plasma levels were measured by enzymelinked immunosorbent assay (R&D Systems).
PBMCs were obtained from blood drawn at randomization and at the time of surgery. 1 Protein extracts were prepared for electrophoretic mobility shift assay. 1 Quantification was performed by densitometric analysis (ImageQuant program), yielding results in arbitrary units.
Total RNA was extracted, quantitative reverse-transcription polymerase chain reaction was performed, and target genes were corrected for GADPH.
Plaque Studies
Specimens were collected and processed 1 using monoclonal antihuman macrophages (HAM-56; DAKO), COX-2 (Cayman), and MCP-1 (Abcam) antibodies. Negative controls using the corresponding IgG were included to check for nonspecific staining. In situ NF-B activity was detected by Southwestern histochemistry. 1 Competition assays with 200-fold excess of unlabeled probe were used as negative controls.
Morphometry was performed with the Olympus semiautomatic image analysis system. 1 Results are expressed as percentage of positive staining/mm 2 (immunohistochemistry) and nuclei staining positive/mm 2 (Southwestern).
Statistical Analysis
Statistical analysis was performed with GraphPAD InStat (Graph-PAD Software). Lipid levels and enzyme-linked immunosorbent assay data were presented as median (interquartile range) and analyzed by the Kruskal-Wallis test. Changes in lipids and enzyme-linked immunosorbent assay levels in every treatment group were assessed by a covariance analysis using the basal levels as the covariate. EMSA, quantitative polymerase chain reaction, and Southwestern and immunohistochemistry data at the end of the study were presented as meanϮ95% confidence interval and analyzed by Mann-Whitney test. Categorical variables were assessed by Fisher's exact test. Differences were considered significant at 2-tailed PϽ0.05.
Results
Clinical data were well-balanced between both groups. Atorvastatin reduced total and low-density lipoprotein cholesterol and PGE 2 plasma levels, whereas no significant changes were observed in the nontreated group (Table) Figure 1) . No significant differences were noted between these parameters of both (Figure 2 ).
Characteristics of Patients

Discussion
We show that atorvastatin 80 mg/d diminishes lipid levels and blood inflammatory mediators (PGE 2 plasma levels, NF-kB activity, and MCP-1 and COX-2 expression in PBMCs) in patients with carotid atherosclerosis within 1 month.
Atorvastatin 80 mg/d decreased macrophage infiltration in plaques as shown after 3 to 4 months of moderate statin treatment. [5] [6] Moreover, NF-B activation, MCP-1, and COX-2 expression were also reduced. This may have been responsible for the reduction in macrophage infiltration, as shown in animal models. 7 Of interest, 40 mg/d pravastatin for 3 months did not affect NF-B activation in carotid atherosclerotic plaques. 5 This suggests that intensive statin treatment has a faster antiinflammatory effect than moderate doses, in accordance with the decrease in atherosclerosis progression observed with high-dose atorvastatin in a recent clinical trial. 8 Nevertheless, our data must be interpreted cautiously, given the small sample size and that it was not a placebo-controlled study.
In conclusion, our findings suggest that intensive treatment with atorvastatin decreases the inflammatory activity of human PBMCs and carotid plaques in 1 month. 
